敬老院1号 管理员Lv12 关闭了本次求助。

说明 求助违规（查看求助规则）：该文献不存在全文(会议摘要、poster、视频等)【积分已退回】

敬老院1号 管理员Lv12 进行了留言

全文如下:
Immune checkpoint blockade (ICB) has improved the management of NSCLC, but only a minority of patients respond and long-lasting remissions are rare. In contrast to findings in other cancers, Martinez-Usatorre et al. report that combining ICB (PD1 antibodies) with antiangiogenic therapy (ANGPT2 and VEGFA blockade) is not beneficial in mouse models of NSCLC. Antiangiogenic therapy increased tumour infiltration by PD1+ Treg cells, which was sustained by tumour-associated macrophages (TAMs) and targeted by PD1 antibodies. Depleting TAMs — using a CSF1R inhibitor and cisplatin — redirected PD1 antibodies to CD8+ T cells, magnifying the tumour response to antiangiogenic immunotherapy.

回复

Jiang 小白 求助人 Lv1 驳回了 上官若男 上传的文件

说明

内容不对

回复

上官若男 Lv6 上传了文件

已驳回 20211204201748-002cb6db-168.pdf (68.89 KB) 回复

Jiang 小白 求助人 Lv1 发起了本次求助